Apellis Pharmaceuticals Inc (APLS)
28.06
-0.19
(-0.67%)
USD |
NASDAQ |
Nov 14, 16:00
28.04
-0.02
(-0.07%)
After-Hours: 20:00
Apellis Pharmaceuticals Net Income (TTM): -250.10M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
Date | Value |
---|---|
September 30, 2024 | -250.10M |
June 30, 2024 | -332.89M |
March 31, 2024 | -417.27M |
December 31, 2023 | -528.63M |
September 30, 2023 | -606.04M |
June 30, 2023 | -657.08M |
March 31, 2023 | -691.02M |
December 31, 2022 | -652.17M |
September 30, 2022 | -634.11M |
June 30, 2022 | -638.42M |
March 31, 2022 | -701.63M |
December 31, 2021 | -746.35M |
September 30, 2021 | -520.16M |
June 30, 2021 | -460.28M |
March 31, 2021 | -359.71M |
December 31, 2020 | -344.87M |
September 30, 2020 | -536.36M |
Date | Value |
---|---|
June 30, 2020 | -470.48M |
March 31, 2020 | -422.96M |
December 31, 2019 | -304.71M |
September 30, 2019 | -228.37M |
June 30, 2019 | -194.10M |
March 31, 2019 | -156.34M |
December 31, 2018 | -127.50M |
September 30, 2018 | -108.87M |
June 30, 2018 | -84.90M |
March 31, 2018 | -63.69M |
December 31, 2017 | -51.01M |
September 30, 2017 | -39.37M |
June 30, 2017 | -35.01M |
March 31, 2017 | -31.10M |
December 31, 2016 | -53.24M |
September 30, 2016 | -49.30M |
December 31, 2015 | -44.56M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-746.35M
Minimum
Dec 2021
-250.10M
Maximum
Sep 2024
-513.76M
Average
-524.39M
Median
Net Income (TTM) Benchmarks
Biomarin Pharmaceutical Inc | 322.29M |
Ionis Pharmaceuticals Inc | -358.81M |
EyePoint Pharmaceuticals Inc | -103.57M |
Cassava Sciences Inc | -17.66M |
Macrogenics Inc | -97.62M |